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Abstract 
Background: The application of advanced imaging technologies for identifying pancreatic cysts has become 
widespread. However, accurately differentiating between low‑grade dysplasia (LGD), high‑grade dysplasia (HGD), and 
invasive intraductal papillary mucinous neoplasms (IPMNs) remains a diagnostic challenge with current biomarkers, 
necessitating the development of novel biomarkers that can distinguish IPMN malignancy.
Methods: Cyst fluid samples were collected from nine IPMN patients (3 LGD, 3 HGD, and 3 invasive IPMN) during 
their pancreatectomies. An integrated proteomics approach that combines filter‑aided sample preparation, stage 
tip‑based high‑pH fractionation, and high‑resolution MS was applied to acquire in‑depth proteomic data of pancre‑
atic cyst fluid and discover marker candidates for IPMN malignancy. Biological processes of differentially expressed 
proteins that are related to pancreatic cysts and aggressive malignancy were analyzed using bioinformatics tools such 
as gene ontology analysis and Ingenuity pathway analysis. In order to confirm the validity of the marker candidates, 
19 cyst fluid samples were analyzed by western blot.
Results: A dataset of 2992 proteins was constructed from pancreatic cyst fluid samples. A subsequent analysis found 
2963 identified proteins in individual samples, 2837 of which were quantifiable. Differentially expressed proteins 
between histological grades of IPMN were associated with pancreatic diseases and malignancy according to ingenu‑
ity pathway analysis. Eighteen biomarker candidates that were differentially expressed across IPMN histological grades 
were discovered—7 DEPs that were upregulated and 11 that were downregulated in more malignant grades. HOOK1 
and PTPN6 were validated by western blot in an independent cohort, the results of which were consistent with our 
proteomic data.
Conclusions: This study demonstrates that novel biomarker candidates for IPMN malignancy can be discovered 
through proteomic analysis of pancreatic cyst fluid.
Keywords: Pancreatic cyst fluid, Intraductal papillary mucinous neoplasm (IPMN), IPMN dysplasia, Biomarker 
candidates, LC–MS/MS
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Background
Intraductal papillary mucinous neoplasms (IPMNs) are 
precancerous lesions that grow in the pancreatic ducts 
and are characterized by papillary growth of the ductal 
epithelium. The production of thick mucinous fluid, 
another hallmark of IPMNs, causes cystic dilation and 
can progress into pancreatic ductal adenocarcinoma [1–
4]. Depending on the malignancy, IPMN is classified as 
low-grade dysplasia (LGD), intermediate-grade dysplasia 
(IGD), high-grade dysplasia (HGD), and invasive IPMN. 
According to the official guidelines for managing pan-
creatic IPMN, only patients with HGD or invasive IPMN 
require surgery, because they are at higher risk of their 
disease developing into cancer [5]. Milder forms of IPMN 
can be managed with active surveillance and do not war-
rant surgical intervention. However, current methods for 
assessing the histological grades of IPMNs are unreliable, 
and as a result, patients with milder IPMN are often sub-
jected to unnecessary operations [6–10].
In clinical practice, MRI and CT scans, cytological 
examination of cyst fluid, measurement of tumor mark-
ers such as carcinoembryonic antigen (CEA) and carbo-
hydrate antigen 19-9 (CA 19-9), and analysis of GTPase 
Kras (KRAS) and guanine nucleotide-binding protein 
alpha subunit (GNAS) mutations are used to categorize 
patients with pancreatic cysts [6, 7, 10–16]. Features of 
pancreatic images in MRI or CT scans are generally used 
to assess the potential malignancy of cysts but have low 
diagnostic accuracy—up to 40% of neoplastic cysts are 
misdiagnosed as pseudocysts, and the overall accuracy 
ranges from 20 to 80% [17–19]. Cytological examination 
of pancreatic cyst fluid is an alternative approach, but it 
has difficulties in identifying the existence of malignancy 
when sufficient sample volumes are unavailable [16, 
20–23]. Differentiating mucinous cysts from other cystic 
lesions by measuring carcinoembryonic antigen levels 
in cyst fluid has relatively low accuracy (79% sensitivity, 
73% specificity) [17, 24]. Similarly, as shown by Frossard 
et al. [25], CA 19-9, a pancreatic cancer marker, also per-
forms poorly in distinguishing mucinous cysts and other 
lesions, with 15% sensitivity and 81% specificity [16]. 
Analyzing GNAS mutations are only applicable for sam-
ples that are acquired during the early stages of IPMN 
[20, 23, 26, 27]. The general consensus is that existing 
methods for diagnosing IPMN histological grades are 
imprecise and unreliable, even when used in tandem [6, 
7, 10, 16, 17, 20].
Because pancreatic cyst fluid contains secreted proteins 
from tumor cells at higher proportions, several groups, 
such as Poersch et al. [28], have concluded that it is a bet-
ter experimental model of IPMN histological grades than 
serum and plasma [16, 29–32]. Consequently, pancreatic 
cyst fluid has been widely favored in recent research on 
IPMN, because it is obtainable by endoscopic ultrasound-
guided fine needle aspiration biopsy, which is minimally 
invasive [6, 25, 33]. Many studies have focused on discov-
ering protein markers that differentiate mucinous from 
nonmucinous cyst fluid and cyst fluid that is related to 
IPMN dysplasia, based on DNA methylation and telom-
erase activity, as demonstrated by Hata et al. [20]. Diag-
nosing histological grades of IPMN using pancreatic cyst 
fluid by proteomic analysis is a relatively unexplored area 
[6, 7, 20, 34, 35]. Thus, the IPMN dysplasia proteome has 
not been characterized extensively.
Cuoghi et al. [36] performed a cursory profiling study 
of the proteomic patterns of pancreatic cyst fluids from 
various cystic lesions, including IPMN, MCN, serous 
cystadenomas, pancreatic neuroendocrine tumors, and 
pseudocysts, identifying 220–727 proteins in these flu-
ids. Specifically, 243 proteins were identified in the 
IPMN groups. Gbormittah et  al. [37] characterized 
glycoproteins and nonglycoproteins in mucinous and 
nonmucinous pancreatic cyst fluid to identify DEPs as 
potential biomarker targets. They found 230 proteins in 
mucinous subtypes and 290 proteins in nonmucinous 
subtypes; the DEPs between mucinous and nonmuci-
nous cyst fluid were associated with lipid metabolism, 
energy metabolism, and stress responses. These studies 
were unable to determine the IPMN histological grades, 
merely differentiating between mucinous and nonmuci-
nous cyst fluid. These recent studies demonstrate that 
the current cyst fluid proteome lacks the coverage to 
extrapolate meaningful conclusions on the molecular 
and biological activities of the identified proteins, which 
ultimately impedes our understanding of IPMN histol-
ogy in terms of proteomic differences and biological 
functions.
In this report, we aimed to comprehensively identify 
pancreatic cyst fluid proteins and discover differentially 
expressed proteins in accordance with histological grades 
of IPMN. Recently, we reported a platform for in-depth 
profiling of pancreatic cyst fluid [38]. Using this plat-
form, the protein expression patterns of pancreatic cyst 
fluid were analyzed on a high-resolution mass spectrom-
eter to discover potential biomarkers of IPMN histologi-
cal grades. Subsequently, we validated some of the 18 
candidate markers by western blot. We report here that 
pancreatic cyst fluid is a valuable source for biomarker 
studies as it contains putative markers related to IPMNs 
and that bioinformatics analyses using identified pro-
teins of cyst fluid enhance our understanding of IPMNs 
at the molecular level. We ultimately intend to discover 
marker candidates that can help patients avoid unneces-
sary operations.
Page 3 of 22Do et al. Clin Proteom  (2018) 15:17 
Methods
Clinical samples
Cyst fluid samples were collected from 9 IPMN patients 
during their pancreatectomies at Seoul National Uni-
versity Hospital (Seoul, South Korea) from April 2013 to 
December 2015. At least 200  μL of cyst fluid was aspi-
rated from each patient. The samples were then snap-fro-
zen in liquid nitrogen and stored at − 80 °C. All patients 
consented to participation in the study in accordance 
with Institutional Review Board guidelines (IRB No. 
1301-095-458). IPMN samples were divided into low-
grade dysplasia (LGD, n = 3), high-grade dysplasia (HGD, 
n = 3), and invasive IPMN (n = 3).
Pancreatic cyst fluid protein sample preparation
Each pancreatic cyst fluid sample was transferred to an 
Eppendorf tube. Viscous samples that could not be pipet-
ted were sonicated briefly (Sonics and Materials Inc., 
USA) to remove the mucus. All samples were centrifuged 
at 15,000  rpm for 20  min at 4  °C, and the supernatant 
was placed into a new tube. The protein concentration 
was estimated using a BCA reducing agent compatibility 
assay kit (Thermo Scientific, Rockford, IL, USA). Equal 
portions of each sample were pooled to create a peptide 
library from 600  µg of proteins. One hundred micro-
grams of individual protein samples were used for label-
free quantification. Cold acetone (Sigma-Aldrich, USA) 
was added to the supernatant to the ratio of 5:1 (v/v) to 
precipitate the proteins. The mixture was vortexed gen-
tly and incubated overnight at − 20  °C. The precipitate 
was centrifuged for 10 min (15,000 rpm at 4 °C), and the 
supernatant was carefully decanted, after which 500  µL 
cold acetone was added to the pellet. After this wash 
step, the pellet was centrifuged for 10 min (15,000 rpm at 
4 °C). The remaining acetone was poured off, and the pel-
let was air-dried for 2 h.
Protein digestion and desalting
The pellet was dissolved in 30 μL of lysis buffer (4% SDS, 
0.1 M DTT, 0.1 M Tris–Cl, pH 7.4). The mixture was gen-
tly vortexed and boiled for 30  min at 95  °C. The boiled 
mixture was then transferred through a 30-kDa cutoff 
filter  (Amicon® Ultra, Millipore, USA) with 300 μL 8 M 
urea (8 M Urea, 0.1 M Tris–Cl, pH 8.5) and centrifuged 
(14,000g, 15 min, 20 °C). This filtration step was repeated 
twice to dilute and lower the SDS concentration. Next, 
200 μL 50 mM IAA (50 mM IAA, 8 M urea, 0.1 M Tris–
Cl, pH 8.5) was added to each sample and incubated 
for 1 h at 25  °C. Each sample was then centrifuged and 
washed twice with 300 μL 8 M urea and then three times 
with 300 μL 40 mM ammonium bicarbonate (ABC).
After the samples were centrifuged, 100  μL 40  mM 
ABC and 0.1 μg/μL trypsin (at a trypsin:sample ratio of 
1:80, wt/wt) were added to each sample and incubated 
for 18 h at 37  °C. Next, the filters (nine individual sam-
ples, one pooled sample) were transferred to new collec-
tion tubes, which were centrifuged after 100 μL 40 mM 
ABC was added. Fifty microliters NaCl was added to 
each individual sample, and 50 μL water was added to the 
pooled sample. The pooled sample underwent an addi-
tional digestion step [39, 40]. Again, the filter unit was 
transferred to a new tube and centrifuged after 200  μL 
8 M urea was added. Then, the unit was centrifuged twice 
with 300  μL 40  mM ABC. One-tenth of the concentra-
tion of trypsin that was used in the first digestion step 
was added with 100  μL 40  mM ABC, and the unit was 
incubated for 18  h at 37  °C. Next, the filter was trans-
ferred to another tube, and the peptides were collected 
by sequential centrifugation with 100  μL 40  mM ABC 
and 50 μL 0.5 M NaCl.
Prior to acidification and desalting, all tryptic pep-
tides were measured by tryptophan fluorescence assay 
to determine the volume that was required to extract 
the same amount of peptides from each sample [41]. The 
equalized amounts of peptides were then set aside for 
label-free quantification. The measured peptides were 
acidified with 10  μL 10% TFA and desalted with home-
made C18-StageTip columns as described [42]. The 
desalted peptides were then lyophilized on a speed-vac-
uum centrifuge and stored at − 80 °C.
Peptide fractionation by high‑pH reverse phase 
fractionation
To increase the number of identified proteins, the pooled 
cyst fluid sample was fractionated using two methods: 
modified stage-tip-based high-pH peptide fractionation 
[43, 44] and offline HPLC high-pH fractionation on an 
Agilent 1260 Bio-inert. For stage-tip fractionation, half of 
the lyophilized peptides were dissolved in 200 μL of load-
ing buffer (15  mM ammonium hydroxide solution, pH 
10, and 2% acetonitrile) and separated on a pipette-based 
C18 RP microcolumn. The column was constructed 
by plugging the bottom of a 200  μL transparent pipette 
tip with C18 Empore disk membrane (3  M, Bracknell, 
UK) and packing the tip with POROS 20 R2 resin. The 
plugged tip was rinsed three times with 100  μL 100% 
methanol and then three times with 100  μL 100% ace-
tonitrile (ACN). The column was then conditioned with 
100  μL of loading buffer using a syringe. The peptides 
were loaded onto the column at pH 10. An ACN gradient 
of 2, 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, 30, 32.5, 
35, 40, 50, 60, 70, 80, and 100% was used to elute 20 frac-
tions, which were collected into six tubes discontinuously 
to distribute eluents of varying hydrophobicity. These six 
fractions were lyophilized in a speed-vacuum centrifuge 
and stored at − 80 °C.
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The remaining half of the lyophilized peptides was dis-
solved in 80  μL of loading buffer (15  mM ammonium 
hydroxide in water, pH 10). The peptides were loaded 
onto the column, and 96 (2 mL Square Collection Plate, 
Waters, UK) fractions were eluted by applying an ACN 
gradient (pH 10, 5–35%) for 40  min at a flow rate of 
0.2 mL/min and washing the column with 90% ACN for 
10 min at 0.2 mL/min. The ACN gradient was established 
by mixing varying proportions of solution A (0.1% formic 
acid in HPLC-grade distilled water) and solution B (0.1% 
formic acid in ACN). The 96 fractions were concatenated 
according to the column number of the plate to produce 
12 pooled fractions. The resulting 12 tubes were lyophi-
lized in a speed-vacuum centrifuge and stored at − 80 °C.
LC–MS/MS analysis
The peptide samples were analyzed using an LC–MS/MS 
configuration, comprising an Easy-nLC 1000 (Thermo 
Fisher Scientific, Waltham, MA, USA) that was coupled 
to a Q Exactive mass spectrometer with a nanoelectro-
spray ion source (Thermo Fisher Scientific, Waltham, 
MA, USA), per our established protocol [38, 44, 45]. Pep-
tides were separated on a 2-column system that was com-
posed of a trap column (75 μm I.D. × 2 cm, C18 3.0 μm, 
100  Å) and an analytical column (50  μm I.D. × 15  cm, 
C18 3.0 μm, 100 Å).
Fractionated peptides were subjected to an ACN gra-
dient (6–60%) for 235 min. The gradient was created by 
mixing solvent A (2% ACN and 0.1% v/v formic acid) and 
solvent B (100% acetonitrile and 0.1% v/v formic acid) at 
various proportions. The spray voltage was set to 2.0 kV 
in positive ion mode, and the temperature of the heated 
capillary was set to 320 °C. Mass spectra were acquired in 
data-dependent mode by top 20 method on an Orbitrap 
analyzer with a mass range of 350–1700 m/z and a res-
olution of 70,000 at m/z 200. HCD scans were acquired 
at a resolution of 17,500. HCD peptide fragments were 
acquired at a normalized collision energy (NCE) of 27. 
The maximum ion injection time for the survey scan and 
MS/MS scan was 20 and 80 ms, respectively. All samples 
were analyzed in three technical replicates.
Raw data search
The MS data from the Q Exactive were processed in 
MaxQuant (version 1.5.5.1 with built-in Andromeda 
search engine) [46]. Precursor MS signal intensities were 
determined, and HCD MS/MS spectra were de-isotoped 
and filtered, such that only the 20  most abundant frag-
ments per 100 m/z range were retained. Protein groups 
were identified by searching the MS and MS/MS data of 
the peptides against the Uniprot human database (2014 
December, 88,717 entries). Both the forward and reverse 
amino acid sequences were taken into account when 
calculating the false discovery rate (FDR). Following 
established target-decoy search procedures [47], search 
results were filtered at FDR < 1% for identifying pep-
tides, modification sites, and proteins. The search was 
conducted in digestion mode trypsin/P, which assumes 
cleavage at carboxyl sides of lysine and arginine, includ-
ing cases where the subsequent residue is a proline.
The following parameters were used in the database 
search: precursor and HCD fragment mass tolerances of 
6 and 20 ppm, respectively; tolerance of up to two missed 
cleavages; carbamidomethylation of cysteine as a fixed 
modification; and oxidation of Met and acetylation of 
protein N-term as variable modifications. The minimum 
peptide length was set to six residues. Peptides were 
assigned to protein groups by the principle of parsimony 
[48–50]. The principle is applied to derive the smallest 
list of probable protein groups that adequately represent 
the identified peptides, which reduces sequence redun-
dancy issues. All proteomics data in this report have been 
deposited in the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org/) through the 
PRIDE partner repository: dataset identifier PXD008302 
[51, 52].
Label‑free quantification and statistical analysis
Label-free quantification (LFQ) and statistical analysis 
were performed in MaxQuant (version 1.5.5.1) and Per-
seus (version 1.5.8.5), respectively, according to our pre-
vious studies [43, 45]. Protein abundance was obtained 
from LFQ intensity values. LFQ intensity was calculated 
as described by the equation by Cox et al. [53]. Each of 
the three histological groups in this study had three bio-
logical replicates, which in turn had three technical rep-
licates each. Thus, a total of 9 LFQ intensity values exist 
per histological group (three biological replicates × three 
technical replicates). LFQ intensity values greater than 
zero were deemed valid. Proteins with at least six valid 
values within a histological group were used in statisti-
cal analysis for label-free quantification. This criterion 
was used to reduce the possibility of analyzing proteins 
that are nonspecific to histological grades. After log2-
transformation of protein intensities, the missing values 
were replaced with expected intensities based on the 
normal distribution (imputation width = 0.3, shift = 1.8) 
of log2-transformed LFQ intensities [43]. Student’s t 
test was applied to the preprocessed dataset of matched 
proteins to detect DEPs across grades of IPMN dyspla-
sia. The comparative pairs for the statistical analysis were 
LGD versus HGD (comparison 1), HGD versus invasive 
IPMN (comparison 2), and LGD versus invasive IPMN 
(comparison 3). A Benjamini–Hochberg FDR thresh-
old of 0.05 was applied to each pair to find significantly 
changed proteins. Subsequently, the expression patterns 
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of overlapping DEPs across two or more pairs were ana-
lyzed to screen for biomarker candidates. DEPs that had 
expression patterns that varied based on the malignancy 
of IPMN were selected as final biomarker candidates. The 
resulting DEPs were subjected to hierarchical clustering 
in Perseus (version 1.5.8.5) with the following param-
eters: Euclidean distance, average linkage, the number of 
clusters of 100, maximal number of iterations of 10, the 
number of restarts of 1, and k-means preprocessing prior 
to clustering.
Bioinformatics analysis
The gene ontologies (GOs) of all DEPs were annotated 
using the DAVID bioinformatics resource tool (https://
david.ncifcrf.gov/) and the UniprotKB database (http://
www.uniprot.org/). The GO analysis included infor-
mation on biological process (BP), cellular component 
(CC), and molecular function (MF). Pathway analysis 
was performed using the KEGG database (http://www.
genome.jp/kegg/). Secretory protein prediction and 
functional annotation were performed using SignalP 4.1 
(http://www.cbs.dtu.dk/services/SignalP/), SecretomeP 
2.0 (http://www.cbs.dtu.dk/services/SecretomeP/), and 
TMHMM, server 2.0 (http://www.cbs.dtu.dk/services/
TMHMM/). Ingenuity pathway analysis (IPA) was used 
to conduct functional analysis (Ingenuity Systems, http://
www.ingenuity.com/). The plasma proteome database 
(PPD) was used to confirm the association between the 
proteins that were identified in human plasma and the 
proteins that were identified in this study [54, 55]. The 
proteins that were identified in our dataset were cross-
referenced with mRNA and protein expression in pan-
creatic sections in the Human Protein Atlas (http://www.
proteinatlas.org/).
Western blot analysis
A total of 19 pancreatic cyst fluid samples—10 LGD, 
4 HGD, and five invasive IPMN—were used to validate 
the candidate markers. Equal volumes of a pooled cyst 
fluid sample were loaded onto each gel to correct for the 
intensity of the blots. Pancreatic cyst fluid samples were 
mixed with 5× SDS loading dye (250  mM Tris–Cl, pH 
6.8, 10% SDS, 50% glycerol, 0.5 M DTT, 0.1% bromophe-
nol blue). Proteins (40  μg, as measured by BCA assay) 
were separated on 10% SDS-PAGE gels and transferred 
to polyvinylidene fluoride (PVDF) membranes (Hybond-
P, GE Healthcare, Pittsburgh, PA, USA). The membranes 
were stained with Ponceau S dye (P7170, Sigma-Aldrich, 
USA), blocked with 5% BSA for 2 h at RT, and incubated 
overnight at 4  °C with the following primary antibod-
ies: rabbit monoclonal anti-HOOK1 (ab150397, Abcam, 
Cambridge, UK) at 1:250, mouse monoclonal anti-
PTPN6 (sc-7289, Santa Cruz Biotechnology, USA) at 
1:1000, and mouse polyclonal anti-SERPINA5 (ab67368, 
Abcam, Cambridge, UK) at 1:100. The membranes were 
then washed five times with Tris-buffered saline and 
Tween-20 (TBS-T) before being incubated with the fol-
lowing HRP-conjugated secondary antibodies: anti-
rabbit (ab6721, Abcam, Cambridge, UK) at 1:1000 and 
anti-mouse (ab6789, Abcam, Cambridge, UK) at 1:2500 
for 2 h at RT. The membranes were developed with ECL 
solution (West-Q chemiluminescent substrate Kit-plus, 
GenDEPOT, Barker, TX, USA), and the signals were visu-
alized on an LAS-4000 (Fujifilm, Japan).
Results
Clinical sample characterization
Pancreatic cyst fluid samples from nine patients were 
classified into three groups: LGD (n = 3), HGD (n = 3), 
and invasive IPMN (n = 3). The samples did not dif-
fer significantly in composition, with the exception of 
serum CEA level and CA 19-9 concentration measured 
by chemiluminescent microparticle immunoassay and 
cyst size (Table  1). The invasive IPMN patient group 
had the highest average CEA and CA19-9 concentra-
tions at 7.67 ± 7.06 and 117.17 ± 142.78  mg/L, respec-
tively. CEA and CA19-9 levels were generally higher in 
the more severe forms of IPMN. The average CEA con-
centration was approximately 3-fold higher for HGD 
than LGD subjects and 7-fold higher in invasive IPMN 
versus LGD. In addition, the average CA19-9 level was 
approximately 2-fold and 30-fold greater for these com-
parisons. Our samples were consistent with several 
publications that have reported that malignant cysts 
tend to be larger, as evidenced by our invasive IPMN 
samples (6.63 ± 3.74  cm) being twice as large as LGD 
(2.93 ± 0.54  cm) and HGD (2.50 ± 0.41  cm) samples on 
average [5, 56–59].
In‑depth analysis of pancreatic cyst fluid
The overall scheme of the study was based on a prot-
eomic platform of cyst fluids that we established earlier 
[38]. In this study, nine individual pancreatic cyst fluid 
samples of various types [LGD (n = 3), HGD (n = 3), and 
invasive IPMN (n = 3)] were used for label-free quan-
tification. All samples were centrifuged, and only the 
supernatant was used. The same portions of individual 
samples were pooled and fractionated to generate a 
peptide library, which increased the depth of the identi-
fied proteins. In contrast, the nine individual samples 
were not fractionated. After a series of sample prepara-
tion steps, LC–MS/MS analysis was performed on a Q 
Exactive mass spectrometer. The MS data were processed 
in MaxQuant (version 1.5.5.1), and the statistical analysis 
was performed in Perseus (version 1.5.8.5) (Fig. 1; Addi-
tional file 1: Fig. S1a).
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In total, 2992 proteins were identified and 2938 pro-
teins were quantified (Additional file 2: Table S1). A total 
of 28,728 peptides were identified, and 553,199 peptide 
spectra matches were found. In the peptide library and 
the nine individual samples, 2778 and 2963 proteins were 
identified, respectively. Comparing the peptide library 
with the individual samples, 2749 proteins (91.9% of all 
identified proteins) were shared (Fig. 2a). In the nine indi-
vidual samples, most of the identified proteins (95.7%) 
were usable for quantitative analysis, as evidenced by the 
2963 and 2837 proteins that were identified and quanti-
fied (Fig.  2b). Approximately 2200–2500 proteins were 
quantified in each sample group. The three IPMN groups 
were similar with regard to the number of quantified pro-
teins (Additional file  1: Fig. S1b). In contrast, there was 
substantial individual variation in the number of identi-
fied and quantified proteins within the same histologi-
cal subgroups. This pattern was observed across all nine 
samples (Additional file 1: Fig. S1c).
On average, the number of identified and quanti-
fied proteins increased by 129 and 83, respectively, in 
individual samples when matched with the peptide 
library. In addition, the number of identified peptides 
rose by 752 on average in individual samples with HGD 
1 displaying the greatest improvement of 2109. (Addi-
tional file  3: Table S2). As shown by the Venn diagram, 
approximately 77% of identified and 63% of quantified 
proteins overlapped in all histological groups and 337 
additional proteins were identified exclusively when the 
search was performed with the generated peptide library. 
Whereas the number of proteins that overlapped in the 
three histological groups decreased by approximately 6% 
when searched without the peptide library (Additional 
file 1: Fig. S1d, e, Additional file 2: Table S1). This result 
implies that the number of proteins that were common 
between individual samples rose due to the contribution 
of the peptide library. As shown in Fig.  3, the percent-
age of overlapping proteins from the biological repli-
cates in each histological grade ranged from 27 to 46%. 
The dynamic range of the proteome spanned over seven 
orders of magnitude overall, but most proteins (95%) 
were expressed within four orders (Fig.  4). Overall, the 
proteins with lower orders of magnitude were analyzed, 
and tumor marker proteins, such as MUC5AC, MUC1, 
and CEA, were quantified with high intensity in the 
dataset.
Comparative analysis using other proteome databases
Our bioinformatics analysis showed that secreted pro-
teins accounted for 60.5% (1810 proteins) of the 2992 
identified proteins (Additional file  1: Fig. S2a, Addi-
tional file  2: Table S1). Across SecretomeP, SignalP, and 
TMHMM, 1527, 682, and 381 proteins were identified, 
respectively (Additional file 1: Fig. S2b, Additional file 2: 
Table S1). Protein accession numbers were converted 
into gene names, and the resulting redundancy was dis-
carded prior to comparative analysis. We compared our 
dataset with the Human Plasma Proteome Database 
to assess the likelihood that the discovered proteins 
are potential blood markers [54, 55]. As a result, 2299 
(79.7%) of the identified proteins were plasma proteins 
(Additional file 1: Fig. S2c, Additional file 2: Table S1). To 
determine whether the discovered proteins are expressed 
in the pancreas, the dataset was crossreferenced with The 
Human Protein Atlas (http://www.proteinatlas.org, May 
31, 2017)—2613 genes had corresponding mRNA entries 
Table 1 Demographic and  clinical characteristics of  the 
study population used in the label-free quantification







Age (years) 69.00 ± 1.41 66.33 ± 8.58 58.33 ± 11.09
Gender
 Male 1 2 1
 Female 2 1 2
Gland type
 Gastric 2 2 1
 Intestinal 0 1 1
 Oncocytic 0 0 1
 Unknown 1 0 0
Duct type
 Main 0 0 1
 Branch 2 1 0
 Mixed 0 2 2
 Unknown 1 0 0
Cyst focality
 Single 2 3 3
 Multiple 1 0 0
 Unknown 0 0 0
Mural nodule
 Y 0 3 3
 N 3 0 0
 Unknown 0 0 0
Cyst location
 Head 1 0 2
 Body/tail 1 3 1
 Mixed 1 0 0
CEA concentration (mg/L) 1.13 ± 0.53 3.07 ± 1.27 7.67 ± 7.06
CA 19‑9 concentration 
(mg/L)
4.00 ± 1.48 6.87 ± 7.17 117.17 ± 142.78
Cyst size
 Cyst size (cm) 2.93 ± 0.54 2.50 ± 0.41 6.63 ± 3.74
 < 3.0 1 2 1
 ≥ 3.0 2 1 2
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and 2021 genes had corresponding protein entries in the 
pancreas (Additional file  1: Fig. S2e, Additional file  2: 
Table S1).
Variation in individual cyst samples
Coefficient of variation (CV%) values were calculated to 
evaluate the reproducibility of the technical and biologi-
cal replicates. The CV% values of log2-transformed LFQ 
intensity sums of technical triplicates of individual sam-
ples ranged from 0.32 to 6.45% (Additional file  4: Table 
S3). All CV% values of log2-transformed LFQ intensities 
of each quantified protein in technical triplicates of indi-
vidual samples were less than 20%. Moreover, the aver-
age CV% value of individual samples ranged from 1.085 
to 1.524% (Additional file 1: Fig. S3a). Pearson correlation 
coefficients of the LFQ intensities of technical triplicates 
and their averages were greater than 0.9 (Fig. 5a–c, Addi-
tional file 1: Fig. S3b–d). These data suggest that the vari-
ation between technical replicates was low. In contrast, 
the variation between biological triplicates was gener-
ally high, based on the Pearson correlation coefficients, 
which ranged from 0.370 (between LGD1 and LGD2) to 
0.789 (between HGD1 and HGD2) (Fig. 5d–f, Additional 
file 1: Fig. S3b–d).
Differentially expressed proteins in IPMN dysplasia
The 1751 proteins that had at least six valid values within 
a histological group were used for the statistical analysis 
Fig. 1 Detailed experimental workflow. Pancreatic cyst fluid samples from nine individuals (3 LGD, 3 HGD, and 3 invasive IPMN) were included 
in this study. After centrifugation, pellets and debris were discarded, and the supernatant was collected for proteomic analysis. Proteins in each 
individual sample and pooled cyst fluid (comprised of equal portions of individual samples) were precipitated with cold acetone. Following FASP 
digestion, the pooled cyst fluids were fractionated using two types of high‑pH fractionation methods. Every prepared sample was analyzed on a Q 
Exactive mass spectrometer
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(Additional file  5: Table S4). By Student’s t test (Benja-
mini–Hochberg FDR = 0.05), 149, 48, and 98 proteins 
were differentially expressed between comparisons 1 
(LGD versus HGD), 2 (HGD versus invasive IPMN), 
and 3 (LGD versus invasive IPMN), respectively (Addi-
tional file 5: Table S4, Fig. 6), 75, 32, and 64 of which were 
upregulated. By unsupervised hierarchical clustering, the 
DEPs clustered by IPMN histology (Additional file 1: Fig. 
S4).
There were 243 DEPs across comparisons 1, 2, and 3. 
Among the 243 DEPs (Fig. 7), 142 were upregulated and 
91 were downregulated in at least 1 comparison group 
(Additional file  6: Table S5). Enriched DEPs were used 
to conduct GO and KEGG pathway analyses to identify 
their overrepresented terms in biological process, molec-
ular function, and cellular component. The DEPs from 
comparisons 1 and 3 were analyzed by ingenuity path-
way analysis (IPA) bioinformatics tool to track biological 
processes that became activated or more pronounced in 
aggressive malignancy.
By GO enrichment analysis, 243 DEPs were involved 
primarily in vesicle-mediated transport and cell sur-
face receptor signaling with regard to biological process. 
The analysis also found that 76.6% of DEPs were extra-
cellular region proteins. The molecular functions of the 
DEPs were primarily associated with peptidase activity 
and regulation (Additional file  1: Fig. S5a–c, Additional 
file  7: Table S6). By KEGG pathway analysis, the 142 
upregulated proteins were associated with the ribosome, 
oxidative phosphorylation, and endocytosis, whereas 
the 91 downregulated proteins were linked to leukocyte 
transendothelial migration, focal adhesion, and ECM-
receptor interaction (Additional file 1: Fig. S5d).
The significantly changed proteins from comparison 
1 and 3 were examined by IPA with regard to biological 
processes that are related to pancreatic cysts and aggres-
sive malignancy. Core analysis in IPA was used to eval-
uate the biological functions that were most likely to 
be affected by changes in expression of proteins in our 
dataset. As a result, 149 DEPs in comparison 1 and 98 
DEPs in comparison 3 were associated with such terms 
as cellular movement and angiogenesis in Diseases and 
Functions, which are indicative of malignancy; the bio-
logical terms that correlated with aggressive malignancy 
are highlighted in yellow (Additional file  1: Fig. S6a, b). 
Cell growth and vasculogenesis were upregulated among 
the DEPs in comparison 1. A total of 98 DEPs in compar-
ison 3 were upregulated in most Diseases and Functions 
terms, except for apoptosis of tumor cell lines—particu-
larly metastasis-related terms, such as cell spreading and 
angiogenesis.
Comparison analysis is usually performed to visualize 
trends in protein expression across several analyses. Con-
sistent with our expectations, the Diseases and Bio func-
tions heat map of the comparison analysis demonstrated 
that the DEPs that were associated with cell movement 
of endothelial cells and angiogenesis were more highly 
expressed in comparison 3 versus 1. The term “apopto-
sis of tumor cell lines” was downregulated in compari-
son 3 but unchanged in comparison 1 (Additional file 1: 
Fig. S6c). A higher percentage of DEPs in comparison 3 
was associated with pancreas-specific diseases, such as 
chronic pancreatitis and associated diseases than DEPs in 
comparison 1 (Additional file 1: Fig. S6d).
Biomarker candidates for IPMN malignancy
Proteins that were shared by at least two comparison 
groups were chosen as the initial marker candidates. Our 
rationale was that significantly changed proteins that are 
common to several comparison groups are more likely 
Fig. 2 Overlap of identified proteins in the individual samples and peptide library and comparison of identified and quantified proteins. a All 
identified proteins in the nine individual samples and peptide library; 91.9% of proteins were identified both in the individual samples and peptide 
library. b All identified proteins and quantified proteins in the nine individual samples; 95.7% of quantifiable proteins overlapped with the identified 
proteins
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to be associated with the malignancy of IPMNs [60]. A 
total of 49 candidates expressed in at least two compari-
son groups were selected from 243 DEPs (Fig. 7). Then, 
the DEPs that had expression patterns that were consist-
ent with the degree of IPMN malignancy were selected 
as the final candidates. Table 2 details the results of the 
statistical analysis of the 49 DEPs, including the p value, 
fold-change, and t test significance for each compari-
son group. Of the 49 DEPs, 38 were secreted proteins 
and 33 were confirmed to be expressed in the pancreas 
as mRNA or proteins in The Human Protein Atlas. In 
addition, 35 proteins were confirmed to be expressed in 
plasma, according to the Human Plasma Proteome Data-
base (Table 2).
Of the 49 shared DEPs between groups, 18 had expres-
sion patterns that were consistent with the degree of 
malignancy. PTPN6, MUC2, TLN1, and YBX1 were 
expressed in lower amounts in LGD but gradually ele-
vated in HGD and invasive IPMN. Conversely, SER-
PINA5, AKR1B10, and TFF1 expression decreased as 
IPMN histological grade progressed. Other proteins, 
such as HOOK1, TYMP, TEX12, FBN1, CLDN18, THY1, 
Fig. 3 Identified and quantified proteins in three individual samples for each histological grade. Identified proteins of three biological replicates 
in LGD (a), HGD (b), and invasive IPMN (c). Quantified proteins of three biological replicates in LGD (d), HGD (e), and invasive IPMN (f) (INV: invasive 
IPMN)
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MUC5AC, CST6, WFDC2, PIK3IP1, and SERPINA4, 
were predominantly expressed in LGD or invasive IPMN 
but not in other groups (Fig. 8, Additional file 1: Fig. S7). 
Based on these results, these 18 proteins were selected as 
potential biomarkers of IPMN dysplasia.
Validation by western blot
Two DEPs (HOOK1 and PTPN6) were validated by 
western blot using 19 pancreatic cyst fluid samples (10 
LGD, 4 HGD, and 5 invasive IPMN). Patient informa-
tion including demographics, cyst characteristics, and 
CEA and CA19-9 levels are provided in Additional file 8: 
Table S7. The results were then compared with the MS 
analysis findings (Fig. 9). Although not every western blot 
sample followed the trend in the MS analysis, the expres-
sion patterns of HOOK1 and PTPN6 generally correlated 
with the LFQ intensity values. HOOK1 was significantly 
upregulated in high-risk IPMN (p value < 0.01), and 
PTPN6 was detected at higher levels in high-risk IPMN 
(p value < 0.05).
Discussion
Most pancreatic neoplasms, which are predominantly 
IPMN, are discovered incidentally during routine 
check-ups [10]. Nevertheless, the lack of a standardized 
guideline adds subjectivity and undesired variability in 
diagnosing the malignancy of IPMN lesions. Because 
the concentrations of tumor biomarkers are higher in 
cyst fluid than in blood, pancreatic cyst fluid of IPMN 
patients was analyzed to discover biomarker candidates 
that could address these inconsistencies in diagnosing 
IPMN malignancy [6, 28]. Thus, analyzing proteins that 
vary significantly, depending on the malignancy of IPMN, 
can identify biomarkers that improve the diagnostic per-
formance of current methods and decrease the number 
of patients who undergo unnecessary operations [12, 20].
As shown in our results, we generated a pancreatic cyst 
fluid proteome that comprised 2992 proteins (Fig.  2a, 
Additional file 2: Table S1). Our proteome had three and 
seven times the number of proteins versus studies by 
Cuoghi [36] and Gbormittah [37], respectively. Further, 
1291 additional proteins were identified over our previ-
ous study [38] by optimizing the standard proteomic 
profiling platform by constructing a peptide library of 
a pooled sample, methodically preparing samples, and 
reproducibly performing label-free quantitative analy-
sis in triplicates (Additional file  1: Fig. S2d). Normally, 
DDA acquisition cannot detect low-abundance proteins 
in individual samples, because high-abundance proteins 
saturate the signal. By pooling and fractionating indi-
vidual samples, these low-abundance proteins became 
distinct and detectable, as evidenced by a dynamic range 
that spanned seven orders of magnitude (Fig. 4). Conse-
quently, the number of identified and quantified proteins 
that were common to all individual samples rose sub-
stantially when the mass spectra of individual samples 
Fig. 4 Dynamic range of quantified proteins. Distribution of expression intensities of quantified proteins show a large dynamic range of abun‑
dance, but 95% of the proteins were expressed within four orders of magnitude. Several tumor marker proteins, such as MUC2, CEA, and KRAS, were 
quantified
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were matched to those of the peptide library (Additional 
file 1: Fig. S1d, e, Additional file 3: Table S2) [61, 62]. This 
increase enabled us to select biomarker candidates from 
a larger pool of DEPs.
Most identified proteins (79.7%) that had entries in the 
Plasma Proteome Database and all marker candidates in 
our study, except AKR1B10, CLDN18, and MUC5AC, 
were confirmed to be expressed in plasma (Addi-
tional file  1: Fig. S2c, Table  2). This result suggests that 
the discovered candidates are potential blood marker 
candidates. Taking into account that 70.0% of proteins 
were expressed in the pancreas, according to The Human 
Protein Atlas, it is probable that the biomarker candi-
dates are specific to the pancreas (Additional file 1: Fig. 
S2e, Additional file 2: Table S1). Considering the bioinfor-
matics analysis results of secreted proteins, we conclude 
that secreted proteins that originate from pancreatic epi-
thelial cells constitute a significant portion of cyst fluid 
(Additional file  1: Fig. S2a, Additional file  2: Table S1). 
The high percentage of matches in these comparative 
Fig. 5 Pearson correlation coefficients of technical replicates (TRs) and biological replicates in each histological group. a–c Pearson correlation 
coefficients of technical replicates in each histological group. Three types of marks indicate the Pearson correlation coefficients of each comparison 
between technical replicates (◆TR1 vs. TR2, ■TR1 vs. TR3, ▲TR2 vs. TR3). Red dots represent the average Pearson correlation coefficient in each 
of the 3 comparisons. a–c indicate LGD, HGD, and invasive IPMN, respectively. Box plot representation of Pearson correlation coefficients between 
each biological replicate in LGD (d), HGD (e), and invasive IPMN (f)
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analyses confirms that virtually all of the debris was dis-
carded and that only cyst fluid was collected during sam-
ple preparation.
The high Pearson correlation coefficients (> 0.9) that 
were obtained from the pairwise correlation analysis 
of LFQ intensity values indicated a strong correlation 
between technical triplicates and that the MS data were 
acquired without bias (Fig.  5a–c, Additional file  1: Fig. 
S3b–d). In contrast, the Pearson correlation coefficient of 
the biological replicates of the histology groups was low, 
as shown in Fig.  5d–f and Additional file  1: Fig. S3b–d, 
primarily due to the wide variety of cyst types, the varia-
tions in cyst size, and the presence of blood contaminants 
[63–65]. One possible source of variation is the contami-
nation of cyst fluid by blood. Fortunately, the samples in 
this experiment were relatively clean, as evidenced by the 
inability to detect albumin and low (intensity rank 1475) 
IgG levels (Fig.  4, Additional file  2: Table S1). Despite 
using relatively clean cyst fluid, the variation between 
individual cyst fluid samples remained large (Additional 
file 1: Fig. S1c, Fig. 5d–f). Based on this result, we infer 
that using contaminated samples will result in even 
greater individual variation.
Selecting proteins that had at least six valid values 
within a histological group mitigated the likelihood of 
analyzing proteins that are not representative of their 
histology group, as evidenced from the low p value of 
the t test, the high fold-change value, and the clear divi-
sion between clusters shown in the heat map (Additional 
file 1: Fig. S4, Additional file 5: Table S4). After eliminat-
ing DEPs that were unique to single comparison group, 
18 proteins that changed expression levels in accord-
ance with the degree of IPMN malignancy were selected 
as biomarker candidates (Table 2, Fig. 8, and Additional 
file 1: Fig. S7). Overall, our stringent criteria—requiring 
at least six valid values in a histological group, rigorous 
statistical analysis parameters, and a consistent expres-
sion pattern across histology groups—significantly 
Fig. 6 Volcano plots based on p values in all comparison groups. To determine the differentially expressed proteins, Student’s t test was performed 
with a Benjamini–Hochberg FDR value of 0.05. The colored dots indicate the proteins that passed the t test for significance between LGD versus 
HGD (a), HGD versus invasive IPMN (b), and LGD versus invasive IPMN (c). The blue dots represent downregulated proteins, and the red dots denote 
upregulated proteins
Fig. 7 Venn diagram of differentially expressed proteins in three 
comparison groups. By Student’s t test (Benjamini–Hochberg 
FDR = 0.05), 149, 48, and 98 proteins were differentially expressed 
between LGD and HGD, between HGD and invasive IPMN, and 
between LGD and invasive IPMN, respectively. A total 243 proteins 
were found to be DEPs when overlapping components of the Venn 
diagram were excluded; 49 proteins were shared in at least two 
comparison groups and are highlighted in white
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Table 2 Detailed statistical analysis of 49 DEPs that were shared in at least two comparison groups













EH domain‑containing protein 1 + 0.00594 − 15.43 + 0.01955 7.35 0.54376 − 2.10
Immunoglobulin lambda variable 
3–21
+ 0.00586 − 18.35 + 0.00001 41.24 0.54057 2.25
Collagen alpha‑1(VI) chain + 0.00224 − 22.78 + 0.01403 5.61 0.19350 − 4.06
Vacuolar protein sorting‑associ‑
ated protein 37B
+ 0.01350 − 6.78 + 0.04669 4.56 0.76562 − 1.49
Ig lambda‑6 chain C region + 0.03265 − 4.96 + 0.02993 20.47 0.31759 4.13
Ras‑related protein Ral‑B + 0.00571 − 5.53 + 0.00111 12.71 0.33130 2.30
Lysozyme C + 0.03497 3.95 + 0.03528 − 5.79 0.66323 − 1.47
Immunoglobulin heavy variable 
1/OR15‑1
0.00000 1.00 + 0.02490 5.06 + 0.00046 7.47
Immunoglobulin lambda variable 
5–45
0.93977 − 1.15 + 0.03513 17.43 + 0.02740 15.11
bAldo–keto reductase family 1 
member B10
0.97902 − 1.08 + 0.00808 − 131.01 + 0.02709 − 140.91
Ig heavy chain V–III region TIL 0.22132 − 1.77 + 0.00288 6.15 + 0.00022 3.48
Ig heavy chain V–III region BUT 0.61619 1.58 + 0.01276 4.09 + 0.03193 6.47
Ig heavy chain V–III region BUR 0.61583 1.72 + 0.03530 5.43 + 0.03177 9.36
Ig heavy chain V–III region ZAP 0.81620 1.29 + 0.01443 6.03 + 0.00587 7.80
Ig alpha‑2 chain C region 0.14392 − 2.13 + 0.02303 3.70 + 0.02778 1.74
aThymidine phosphorylase 0.89045 − 1.25 + 0.00774 48.91 + 0.01333 39.00
aTestis‑expressed sequence 12 
protein
0.75598 − 1.40 + 0.01204 16.69 + 0.00379 11.94
aProtein Hook homolog 1 0.33603 2.29 + 0.00053 50.05 + 0.00000 114.50
Collagen alpha‑1(XV) chain + 0.00001 − 11.37 0.54289 1.75 + 0.01252 − 6.49
Prosaposin + 0.01353 − 2.27 0.69798 1.16 + 0.00131 − 1.95
bPhosphoinositide‑3‑kinase‑
interacting protein 1
+ 0.00707 − 7.41 0.00000 1.00 + 0.01999 − 7.35
bThy‑1 membrane glycoprotein + 0.00966 − 8.39 0.00000 1.00 + 0.01176 − 10.48
Latent‑transforming growth fac‑
tor beta‑binding protein 2
+ 0.01295 − 30.47 0.83621 1.13 + 0.02886 − 26.88
Protein disulfide‑isomerase A3 + 0.00534 27.04 0.64689 − 1.78 + 0.00176 15.23
Agrin + 0.01010 − 95.04 0.64723 1.58 + 0.03007 − 59.97
Alpha‑1‑antichymotrypsin + 0.00041 − 8.93 0.52129 1.65 + 0.01226 − 5.40
Collagen alpha‑1(IV) chain + 0.00000 − 23.08 0.36550 2.54 + 0.01235 − 9.09
bTrefoil factor 1 + 0.03148 − 4.27 0.32370 − 4.75 + 0.03214 − 20.28
bPlasma serine protease inhibitor + 0.00000 − 3.00 0.07044 − 2.33 + 0.00013 − 7.00
Guanine nucleotide‑binding 
protein G(k) subunit alpha
+ 0.00446 − 7.09 0.57151 1.44 + 0.01032 − 4.92
Guanine nucleotide‑binding 
protein G(k) subunit alpha
+ 0.00042 − 12.58 0.94988 − 1.07 + 0.00077 − 13.45
Collagen alpha‑3(VI) chain + 0.00016 − 41.81 0.61089 2.11 + 0.00316 − 19.85
aTyrosine‑protein phosphatase 
non‑receptor type 6
+ 0.02363 4.39 0.50095 1.58 + 0.00391 6.95
bKallistatin + 0.01495 − 6.30 0.68656 1.42 + 0.01178 − 4.45
bFibrillin‑1 + 0.00000 − 57.02 0.43700 1.93 + 0.00012 − 29.49
bClaudin‑18 + 0.00001 − 14.94 0.67515 − 1.49 + 0.00101 − 22.20
Coronin‑7 + 0.00858 6.09 0.85877 − 1.18 + 0.01207 5.15
aNuclease‑sensitive element‑
binding protein 1
+ 0.04238 6.17 0.62145 1.67 + 0.00138 10.30
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Table 2 continued













Histone H3.1 + 0.00023 10.62 0.25248 − 2.30 + 0.01205 4.62
bMucin‑5AC + 0.02741 − 15.38 0.69722 − 1.94 + 0.02010 − 29.87
aMucin‑2 + 0.00006 7068.07 0.76813 − 3.54 + 0.03333 1996.84
bWAP four‑disulfide core domain 
protein 2
+ 0.00554 − 13.23 0.83040 − 1.38 + 0.00690 − 18.23
bCystatin‑M + 0.01152 − 19.49 0.00000 1.00 + 0.03235 − 13.72
BPI fold‑containing family B 
member 1
+ 0.00026 − 27.59 0.49944 1.78 + 0.00180 − 15.53
Intelectin‑1 + 0.01505 844.39 0.76240 − 3.48 + 0.01605 242.93
aTalin‑1 + 0.03653 8.08 0.60098 1.46 + 0.02980 11.78
Basement membrane‑specific 
heparan sulfate proteoglycan 
core protein
+ 0.00003 − 114.37 + 0.00582 13.69 + 0.03552 − 8.35
Histone H3 + 0.00007 22.86 + 0.01650 − 3.15 + 0.00843 7.26
Cadherin‑related family member 
2
+ 0.00024 − 52.14 + 0.02477 13.15 + 0.02747 − 3.96
Protein name SignalP SecretomeP TMHMM The Human Protein Atlas Human plasma proteome
Passed Passed Passed RNA expression Protein expression Included
EH domain‑containing protein 1 – – – Y – Y
Immunoglobulin lambda variable 3–21 Y Y – – – –
Collagen alpha‑1(VI) chain Y – – Y – Y
Vacuolar protein sorting‑associated protein 
37B
– – – Y Y Y
Ig lambda‑6 chain C region – Y – – – –
Ras‑related protein Ral‑B – – – Y Y –
Lysozyme C Y Y – Y Y Y
Immunoglobulin heavy variable 1/OR15‑1 Y Y – – – –
Immunoglobulin lambda variable 5–45 Y Y – – – –
bAldo–keto reductase family 1 member B10 – – – – – –
Ig heavy chain V–III region TIL – Y – – – –
Ig heavy chain V–III region BUT – Y – – – –
Ig heavy chain V–III region BUR – Y – – – –
Ig heavy chain V–III region ZAP – – – – – –
Ig alpha‑2 chain C region – Y – – – Y
aThymidine phosphorylase – Y – Y – Y
aTestis‑expressed sequence 12 protein – Y – – – Y
aProtein Hook homolog 1 – – – Y – Y
Collagen alpha‑1(XV) chain – – – Y – Y
Prosaposin Y Y – Y Y Y
bPhosphoinositide‑3‑kinase‑interacting 
protein 1
Y – – Y – Y
bThy‑1 membrane glycoprotein Y – – Y – Y
Latent‑transforming growth factor beta‑
binding protein 2
Y – – Y – Y
Protein disulfide‑isomerase A3 – – – Y Y Y
Agrin Y – – Y – Y
Alpha‑1‑antichymotrypsin Y Y – Y Y Y
Collagen alpha‑1(IV) chain Y – – Y – Y
bTrefoil factor 1 Y Y – Y – Y
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increased the probability of finding more credible bio-
marker candidates.
All 18 biomarker candidates were associated with pan-
creatic disease and malignancy (Additional file  9: Table 
S8). With the exception of HOOK1, TEX12, TLN1, and 
PIK3IP1, all candidates are expressed in pancreatic tissue 
[66–94]. Twelve candidates were associated with pan-
creatic diseases, such as IPMN, pancreatic ductal adeno 
carcinoma (PDAC), and pancreatitis [66–79, 81–85, 87, 
88, 92–97]. According to Tanaka, CLDN18 is an early-
stage marker of PDAC and is elevated in high-grade ver-
sus low-grade lesions, consistent with our data [5]. Two 
types of mucin proteins were selected as biomarker can-
didates and have been examined in studies on IPMN and 
pancreatic cancer. Our protein expression patterns were 
consistent with those of prior studies. One of the two 
mucin biomarkers, MUC5AC, is expressed at high levels 
during the early stages of pancreatic ductal dysplasia but 
is low in high-grade tumors [70, 72]. MUC2 is expressed 
in IPMNs but not normal pancreatic tissue or PDAC [70].
PTPN6, YBX1, TYMP, CLDN18, WFDC2, SERPINA4, 
TFF1, MUC2, MUC5AC, CST6, THY1, and AKR1B10 
overexpressed in PDAC and pancreatitis. PTPN6 has 
not been reported in human pancreatic samples but has 
been observed in PANC-1 cell lines and a rat model of 
pancreatitis [95, 96]. The upregulated proteins, YBX1 
and TYMP, are expressed at higher levels in PDAC ver-
sus normal tissue, a pattern that is consistent with our 
proteomic data [87, 88]. In addition, these candidates are 
overexpressed in other types of cancer, such as breast and 
bladder cancer [98–101]. The remaining six candidates, 
except SERPINA4 and MUC2, are overexpressed in 
PDAC [66–68, 71, 79, 81, 93]. These proteins are involved 
in tumor progression and differentiation. Accordingly, 
they are regarded as marker candidates of various can-
cer types. WFDC2 is a potential early diagnostic marker 
of gynecological cancers, such as ovarian and endome-
trial cancer [102]. Moreover, serum levels of WFDC2 
are indicative of ovarian cancer [103]. TFF1, THY1, and 
AKR1B10 are associated with various cancers and have 
Table 2 continued
Protein name SignalP SecretomeP TMHMM The Human Protein Atlas Human plasma proteome
Passed Passed Passed RNA expression Protein expression Included
bPlasma serine protease inhibitor Y Y – Y – Y
Guanine nucleotide‑binding protein G(k) 
subunit alpha
– Y – Y Y Y
Guanine nucleotide‑binding protein G(k) 
subunit alpha
Y – – Y Y Y
Collagen alpha‑3(VI) chain Y – – Y – Y
aTyrosine‑protein phosphatase non‑recep‑
tor type 6
– – – Y – Y
bKallistatin Y Y – Y Y Y
bFibrillin‑1 Y – – Y – Y
bClaudin‑18 – – Y Y – –
Coronin‑7 – – – Y Y Y
aNuclease‑sensitive element‑binding 
protein 1
– Y – Y Y Y
Histone H3.1 – Y – – Y –
bMucin‑5AC Y – – – – –
aMucin‑2 Y – – – – Y
bWAP four‑disulfide core domain protein 2 Y Y Y Y – Y
bCystatin‑M Y Y – – – Y
BPI fold‑containing family B member 1 Y Y Y – – Y
Intelectin‑1 Y Y – Y – Y
aTalin‑1 – – – Y Y Y
Basement membrane‑specific heparan 
sulfate proteoglycan core protein
Y – – Y Y Y
Histone H3 – Y – – Y –
Cadherin‑related family member 2 Y Y Y – – Y
a Dominantly expressed in invasive IPMN
b Dominantly expressed in LGD
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Fig. 8 Six biomarker candidates among 18 proteins that had expression patterns that were consistent with the degree of IPMN malignancy. HOOK1 
(a), PTPN6 (b), and MUC2 (c) were predominantly expressed in invasive IPMN. FBN1 (d), CLDN18 (e), and SERPINA5 (f) were primarily expressed in 
LGD (*<p value 0.05; **<p value 0.01, ***<p value 0.001, ****<p value 0.0001, NS not significant)
Fig. 9 Validation of HOOK1 and PTPN6 as potential biomarker targets by western blot. A total of 19 pancreatic cyst fluid samples were analyzed by 
western blot to validate the relative abundance of HOOK1 and PTPN6. The immunoblotting results were consistent with our MS results. a HOOK1 
was overexpressed in high‑risk IPMN in the proteomic (p value < 0.001) and western blot analyses (p value < 0.01). b PTPN6 was overexpressed 
in high‑risk IPMN in the proteomic (p value < 0.001) and western blot analyses (p value < 0.05) (*<p value 0.05, **<p value 0.01, ***<p value 0.001, 
****<p value 0.0001, NS not significant, INV invasive IPMN)
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been implicated as biomarker candidates [104–108]. 
Although it is unknown whether SERPINA4 mediates 
the progression of pancreatic cancer, it is an early marker 
of severity in acute pancreatitis [97]. These studies have 
demonstrated that our final list comprises bona fide can-
didate markers for IPMN. Our report has significance 
as the first study to discover the following marker can-
didates of IPMN: HOOK1, TEX12, TLN1, SERPINA5, 
FBN1, and PIK3IP1. With the exception of TEX12, these 
proteins are associated with other cancers, such as hepa-
tocellular carcinoma, breast cancer, and prostate can-
cer [109–121]. Considering the literature regarding the 
18 candidates, it is likely that they are related to IPMN 
malignancy, except for TEX12.
In order to confirm the validity of the aforementioned 
marker candidates, we compared our MS analysis results 
with western blot results. Western blot with cyst fluids is 
difficult due to the lack of housekeeping proteins, such 
as alpha-tubulin and beta-actin. To address this issue, we 
used 0.1% Ponceau S solution as a loading control (Addi-
tional file  1: Fig. S8, Additional file  10: Table S9) [122, 
123]. The CV% of the intensities of individual samples 
was 14.19%, indicating that approximately equal amounts 
had been loaded onto the SDS-PAGE gels. Three DEPs 
were selected for further validation: two upregulated 
(HOOK1 and PTPN6) and one downregulated protein 
(SERPINA5). The selection criteria for validation were a 
low p value, high LFQ intensities, and a lack of an asso-
ciation with IPMN in the literature (which suggests 
novelty).
HOOK1 was highly expressed in HGD and inva-
sive IPMN compared with LGD (p < 0.01). Although 
the difference in PTPN6 was not statistically significant 
between the three comparison groups, its overall expres-
sion pattern underwent similar changes as in the MS 
results (Additional file 1: Fig. S9a, b). The expression pat-
tern of SERPINA5 was not consistent with the MS analy-
sis and was higher in high-risk IPMN (Additional file 1: 
Fig. S9c). This inconsistency might have resulted from 
the inherent property of western blots, which depends 
on the affinity between an antibody and a single antigenic 
epitope [124–132]. Thus, if the antibody has weak affin-
ity for the epitope, the western blot results would not be 
an accurate measure of protein abundance. In this regard, 
although western blot has been the standard assay in pro-
teomics, targeted proteomic analysis might be a better 
alternative for verifying our quantitative MS data.
Conclusions
We have identified 2992 proteins in IPMN cyst fluid sam-
ples using mass spectrometry techniques. Our investi-
gation demonstrates that the use of a peptide library is 
beneficial, because the increased number of identified 
proteins provides a wider selection to choose from as 
biomarkers. This is evident from our dataset, which con-
tains the largest number of proteins for pancreatic cyst 
fluid. Our in-depth data on the pancreatic cyst fluid pro-
teome will be a valuable resource for pancreatic disease 
research.
Our bioinformatics analysis concluded that upregu-
lated DEPs were associated with pancreatic cell prolif-
eration and aggressive malignancy. Through statistical 
analysis, we designated 18 biomarker candidates that 
changed expression levels, depending on the histologi-
cal grade of IPMN. Among them, two upregulated DEPs 
were consistent with our western blot analysis. The litera-
ture has also concluded that these proteins are involved 
primarily in pancreatic diseases and malignancy, ren-
dering them promising biomarker candidates of IPMN 
malignancy. In future studies, we plan to collect a suffi-
cient amount of cyst fluid samples from more patients to 
test the performance of these biomarkers by immunoas-
say and multiple reaction monitoring (MRM).
Additional files
Additional file 1. Supplementary Figures S1–S9.
Additional file 2. Table S1. List of identified proteins. MS information on 
identified and quantitated proteins is listed consecutively. SignalP and 
SecretomeP were used to identify the secreted proteins, whereas TMHMM 
was used to identify transmembrane proteins. The Human Plasma 
Proteome Database confirmed the association between the proteins that 
were identified in human plasma and the identified proteins of this study. 
Identified proteins in our dataset were crossreferenced with pancreatic 
expression in the Human Protein Atlas. LFQ intensities of individual 
samples were used for further statistical analysis. The additional proteins 
searched exclusively in the presence of peptide library were highlighted 
as the additional column in this table.
Additional file 3. Table S2. The number of identified and quantified 
proteins in individual samples searched with and without the peptide 
library. The number of identified and quantified proteins increased by 129 
and 83, respectively, on average per individual samples when searched 
with and without the peptide library. In the same manner, the number 
of identified peptides rose by 752 on average in individual samples with 
HGD1 presenting the greatest improvement of 2109.
Additional file 4. Table S3. Coefficient of variation (CV%) values of the 
sums of logarithm base two‑transformed LFQ intensities of technical 
triplicates. The CV% values were calculated in each pancreatic cyst fluid 
sample (Technical replicate 1: TR1, Technical replicate 2: TR2, Technical 
replicate 3: TR3).
Additional file 5. Table S4. Results of the statistical analysis. Statistical 
significance, p values, and fold‑changes for 1751 proteins by Student’s t 
test (Benjamini–Hochberg FDR = 0.05) in three comparison sets (compari‑
son set 1, LGD versus HGD; comparison set 2, HGD versus invasive IPMN; 
comparison set 3, LGD versus Invasive IPMN).
Additional file 6. Table S5. List of exclusively upregulated, exclusively 
downregulated, and up‑ or downregulated proteins in all comparison 
groups. Of the 243 DEPs, 142 were upregulated and 91 were downregu‑
lated in at least one comparison group; 10 proteins were up‑ or down‑
regulated by Student’s t test (INV: invasive IPMN).
Additional file 7. Table S6. Gene ontology analysis results. GO annotation 
was performed using the DAVID bioinformatics tool. The p value (modified 
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